Mylan pulls diabetes med after another labeling error

April 14, 2022

Mylan Pharmaceuticals, now a Viatris company, is recalling one batch of its insulin med after labeling errors – again.

The company will yank one lot of its insulin glargine injection because it is possible some of the vials have missing labels. The product is Viatris' glargine-yfgn, an unbranded interchangeable biosimilar for Sanofi’s Lantus. Viatris' insulin glargine is different from its branded insulin product, Semglee, which it had to recall back in January thanks to a similar issue.

This time, the batch getting pulled comes from Indian manufacturer Biocon and was distributed by Mylan Specialty in the U.S. from December 9 to March 4. The recall affects the 10mL vials from batch #BF21002800 that are set to expire in August 2023. It is a long-acting insulin product that is approved for use in adults and kids with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.

The current missing labels might cause confusion for patients taking more than one type of insulin, according to Viatris. As of right now, the company has received no reports of adverse events related to the recall.